仅次于流感 这种病毒流行强度增强 近两月中招人数比去年多5倍
Di Yi Cai Jing·2025-12-25 09:04

Core Viewpoint - The incidence of hand, foot, and mouth disease (HFMD) has significantly increased in November compared to the same period last year, with notable reports from various regions in China indicating a surge in cases [1][3]. Summary by Sections Disease Incidence - In November, Guangdong reported 28,900 cases of HFMD, ranking second among Class B infectious diseases, following influenza [1]. - Jiangsu's report indicated that HFMD was among the top three Class B infectious diseases, alongside influenza and other infectious diarrhea, accounting for 99.83% of reported cases [1]. - Nationally, HFMD cases reached 269,300 in November, with one reported death [1]. - In October, the total number of HFMD cases was 388,700, with no deaths recorded [3]. Seasonal Trends - The cumulative number of HFMD cases for October and November 2025 reached 658,000, over six times higher than the same period in 2024 [3]. - Historical data shows that HFMD cases typically increase starting in April, peaking in the spring-summer and experiencing a smaller peak in the fall [3]. - This year, the fall outbreak of HFMD has been stronger than the spring-summer season, with approximately 397,300 cases reported from May to July [3]. Clinical Observations - Clinical observations indicate that this year's HFMD cases exhibit more pronounced symptoms, with rashes appearing in areas beyond the typical hands, feet, and mouth [4]. - As of December, there has been a noticeable decrease in HFMD patients [4]. Viral Strains and Vaccine Development - The predominant strain causing this year's HFMD outbreak is Coxsackievirus A6, which is associated with more severe symptoms and a higher fever [6]. - A study indicated that Coxsackievirus A6 has become a major pathogen for severe HFMD cases in China, with evolving strains posing outbreak risks [6]. - Currently, the only approved vaccine for HFMD in China is the EV-A71 vaccine, which does not provide protection against Coxsackievirus A6, highlighting the need for further vaccine development [6].